Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Genome-wide maps of H3K4me2 and DNase I hypersensitivity sites in prostate cancer cell line LNCaP and breast cancer cell line MCF-7.


ABSTRACT: We report the high-throughput profiling of histone modification and DNase I hypersensitivity sites in prostate cancer and breaset cancer cells. We found that while AR binding is associated with nucleosome depletion, ER binding is not. We showed that a quantitative measure of DNase I hypersensitivity changes is a powerful tool in indentifying transcription factor cistromes. Examination of histone modification marked nucleosomes and Dnase I hypersensitivity in prostate cancer and breast cancer cells with and without hormone treatment.

ORGANISM(S): Homo sapiens

SUBMITTER: Housheng He 

PROVIDER: E-GEOD-33216 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics.

He Housheng Hansen HH   Meyer Clifford A CA   Chen Mei Wei MW   Jordan V Craig VC   Brown Myles M   Liu X Shirley XS  

Genome research 20120416 6


Transcription factor cistromes are highly cell-type specific. Chromatin accessibility, histone modifications, and nucleosome occupancy have all been found to play a role in defining these binding locations. Here, we show that hormone-induced DNase I hypersensitivity changes (ΔDHS) are highly predictive of androgen receptor (AR) and estrogen receptor 1 (ESR1) binding in prostate cancer and breast cancer cells, respectively. While chromatin structure prior to receptor binding and nucleosome occupa  ...[more]

Similar Datasets

2012-03-25 | GSE33216 | GEO
2010-03-09 | E-GEOD-20042 | biostudies-arrayexpress
| PRJNA316839 | ENA
2012-08-17 | E-GEOD-31151 | biostudies-arrayexpress
| PRJNA381864 | ENA
2012-01-30 | E-GEOD-27919 | biostudies-arrayexpress
2023-07-20 | E-MTAB-12990 | biostudies-arrayexpress
2012-02-17 | E-GEOD-35875 | biostudies-arrayexpress
2007-09-30 | GSE8962 | GEO
| PRJNA322264 | ENA